一些研究表明MutS同源物2(MSH2)在许多癌组织中高表达。从癌症基因组图谱(TCGA)数据库收集转录组表达数据。我们分析了MSH2在正常组织和肿瘤组织中的表达,MSH2表达与各种预后因素之间的关系,以及MSH2表达与总生存期之间的关系,疾病特异性生存,和无进展间隔。我们还检查了子宫内膜癌和正常子宫内膜组织之间的MSH2启动子甲基化,并确定MSH2甲基化在子宫内膜癌中的预后价值。与正常组织相比,MSH2在子宫内膜癌肿瘤组织中高表达。高MSH2表达可能是OS的独立预后因素,DSS,和PFI。Further,MSH2高表达与年龄和组织学类型有关,但不是BMI,临床分期,肿瘤侵袭,或其他临床特征。MSH2启动子甲基化在子宫内膜癌中显著低于正常组织。此外,MSH2电平,操作系统,DSS,PFI与BMI相关,年龄,肿瘤侵袭,和组织学类型。ssGSEA显示MSH2表达与Th2细胞浸润呈正相关,Tcm细胞,T辅助细胞,和Tgd细胞,而它与NKCD56明亮细胞呈负相关,pDC细胞,iDC电池,细胞毒性细胞,和中性粒细胞。子宫内膜癌中MSH2表达增加和MSH2甲基化减少预示预后不良。MSH2可作为子宫内膜癌诊断和预后的生物标志物和作为免疫治疗的靶点。
Several studies have shown that MutS homolog 2 (
MSH2) is highly expressed in many cancer tissues. Transcriptome expression data were collected from the Cancer Genome Atlas (TCGA) database. We analyzed the expression of
MSH2 in normal and tumor tissues, the relationship between
MSH2 expression and various prognostic factors, and the relationship between MSH2 expression and overall survival, disease specific survival, and progression free interval. We also examined MSH2 promoter methylation between endometrial cancer and normal endometrial tissues, and identified the prognostic value of
MSH2 methylation in endometrial cancer. MSH2 was highly expressed in endometrial cancer tumor tissues compared with normal tissues. High
MSH2 expression might be an independent prognostic factor for OS, DSS, and PFI. Further, high MSH2 expression was correlated with age and histological type, but not with BMI, clinical stage, tumor invasion, or other clinical features. MSH2 promoter methylation in endometrial cancer was significantly lower than in normal tissues. Additionally, MSH2 levels, OS, DSS, and PFI were associated with BMI, age, tumor invasion, and histological type. ssGSEA showed that MSH2 expression was positively correlated with the infiltration of Th2 cells, Tcm cells, T helper cells, and Tgd cells, whereas it was negatively correlated with NK CD56 bright cells, pDC cells, iDC cells, cytotoxic cells, and neutrophils. Increased
MSH2 expression and reduced
MSH2 methylation in endometrial cancer predicts poor prognosis. MSH2 may be used as a biomarker for the diagnosis and prognosis of endometrial cancer and as an immunotherapy target.